Merkel cell carcinoma: a clinicopathological study of 10 cases
10.3760/cma.j.cn112151-20201224-00957
- VernacularTitle:Merkel细胞癌10例临床病理学分析
- Author:
Yongyou LUO
1
;
Qinjun SU
;
Yanjun ZHU
;
Peizhong JI
;
Jianwu MA
;
Bin LIU
;
Yanli YANG
Author Information
1. 解放军联勤保障部队第940医院病理科，兰州 730000
- Keywords:
Carcinoma, Merkel cell;
Pathology, clinical;
Immunohistochemistry
- From:
Chinese Journal of Pathology
2021;50(8):915-918
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinicopathological features, differential diagnosis and prognosis of Merkel cell carcinoma (MCC).Methods:The clinical and pathological data of 10 patients with MCC were collected at the 940th Hospital of PLA. The histological characteristics were examined. Immunohistochemical EnVision method was used to detect thyroid transcription factor-1 (TTF1), broad-spectrum cytokeratin (CKpan), CK20, S-100, Ki-67, CD56, chromogranin A, synaptophysin and other markers in the 10 cases.Results:Intradermal MCC of the skin showed a nested, cord-like, cribriform distribution, polygonal cells, uniform size, and lack of cytoplasm. Tumor cell nuclei were large and round, with clear nuclear membranes, fine and scattered chromatin, absence of nucleoli, and mitotic figures of 10 per 50 high power fields. Among them, one patient had sarcoma and squamous cell carcinoma in situ, one patient had squamous cell carcinoma in situ, and one patient had unique cell morphology. Immunohistochemical staining showed that all cancer cells expressed CKpan, synaptophysin and CD56. There were seven cases with perinuclear dot-like positivity of CK20. Six MCCs expressed chromogranin A to varying degrees, while 2 MCCs were weakly positive for p63. The nuclear positive index in the Ki-67 hotspot area was 60%.Conclusion:The histology of MCC varies. Rendering a correct diagnosis of MCC requires adequate sampling, close correlation with clinical history and rational use of immunohistochemical staining. The treatment requires standardized surgery, postoperative radiotherapy and multimodal chemotherapy. Immunotherapy may replace the traditional treatment in the future.
